Stay updated on Olaparib in BRCA Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Olaparib in BRCA Ovarian Cancer Clinical Trial page.

Latest updates to the Olaparib in BRCA Ovarian Cancer Clinical Trial page
- ChecktodayChange DetectedThe site footer revision changes from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check8 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for the olaparib trial in BRCA-mutated ovarian cancer, including its design, eligibility criteria, outcomes, locations, and data-sharing resources, replacing a 403 error page.SummaryDifference98%

- Check15 days agoChange DetectedThe ClinicalTrials.gov footer now lists revision v3.8.0 instead of v3.7.2. The study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA sitewide NIH notice about the terminology transition appears above the study record, and the site revision advances from v3.7.1 to v3.7.2. The study record itself remains a 403 error page.SummaryDifference1%

- Check43 days agoChange DetectedThe footer identifies the site as revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study details with an access-denied message.SummaryDifference17%

Stay in the know with updates to Olaparib in BRCA Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Olaparib in BRCA Ovarian Cancer Clinical Trial page.